DDSR-HTS provides scalable screening platforms to generate hit and lead compounds for drug discovery and development. This approach can also be used to facilitate the discovery of molecular probes for mechanism of action (MOA) studies.
We offer the following services:
1) Assay adaption and development: Assays provided by investigators can be adapted to HTS on multiwell plates or developed from existing methods as supported by statistical validation
2) High throughput screening: Pilot screening, primary screening, and secondary screening against target proteins with a wide variety of readouts such as fluorescence, luminescence, NanoBRET, and AlphaLISA
3) High content screening: Spinning disk confocal microscopy and flow cytometry on up to 384-well plates are offered for primary and secondary screening against cellular phenotypes or specific targets using laser-based excitation of fluorophores at 405 nm, 488 nm, 561 nm, and 640 nm
4) Hit validation: Verification of compound activity using replicated dose-response studies
5) Collections of plated compounds: copies of libraries, collections of cherry-picked compounds, and compound plates arrayed for dose-response studies
6) Data analysis: Quantitative assessments of HTS data and high content imaging data
7) Grantwriting assistance: Project descriptions, letters of support, descriptions of facilities and equipment, and consultation on generation of preliminary data for grant applications
8) Supporting services: Facilitating access to experts in medicinal chemistry (e.g. hit-to-lead and lead optimization studies), drug development (PK/PD), and translational research for preclinical studies and planning for clinical trials
9) Project management: Electronic notebooks and data management strategies are offered as part of project planning, initiation, execution, monitoring, and closure